Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.71 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.64 |
| ▸ | SMPD1 | P17405 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 3/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.59 |
| ▸ | GAA | P10253 | 2/20 | 0.59 |
| ▸ | CASP3 | P42574 | 2/20 | 0.59 |
| ▸ | APAF1 | O14727 | 1/20 | 0.59 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.59 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.59 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.59 |
| ▸ | GSK3B | P49841 | 2/20 | 0.54 |
| ▸ | CMA1 | P23946 | 1/20 | 0.54 |
| ▸ | DRD2 | P14416 | 1/20 | 0.53 |
| ▸ | DRD4 | P21917 | 1/20 | 0.53 |
| ▸ | DRD3 | P35462 | 1/20 | 0.53 |
| ▸ | GSK3A | P49840 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30100692 | 1.00 | POLB (0.71) | POLBL3MBTL1SMPD1MEN1KMT2A | |
| SCHEMBL30100689 | 1.00 | POLB (0.71) | POLBL3MBTL1SMPD1MEN1KMT2A | |
| SCHEMBL4321402 | 0.92 | MEN1 (0.71) | POLBL3MBTL1SMPD1MEN1KMT2A | |
| SCHEMBL14938439 | 0.87 | MEN1 (0.71) | POLBL3MBTL1MEN1KMT2AGAA | |
| SCHEMBL29173745 | 0.86 | CMA1 (0.54) | POLBL3MBTL1MEN1KMT2AGAA | |
| SCHEMBL30806382 | 0.85 | POLB (0.66) | POLBL3MBTL1MEN1KMT2AGAA | |
| SCHEMBL25557092 | 0.84 | L3MBTL1 (0.58) | POLBL3MBTL1MEN1KMT2AGAA | |
| SCHEMBL31399122 | 0.84 | L3MBTL1 (0.58) | POLBL3MBTL1MEN1KMT2AGAA | |
| SCHEMBL29880432 | 0.84 | POLB (1.00) | POLBL3MBTL1MEN1KMT2AGAA | |
| SCHEMBL10688767 | 0.84 | POLB (1.00) | POLBL3MBTL1MEN1KMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025092818-A1 | PYRIDINE DERIVATIVE AND USE THEREOF IN MEDICINE | 康百达（四川）生物医药科技有限公司 | 2025-05-08 | — | — | WO | disclosed |
| CN-119462695-A | Pyridine derivative and application thereof | 康百达（四川）生物医药科技有限公司 | 2025-02-18 | — | — | CN | disclosed |
| CN-117510407-A | Visible light catalyzed olefin hydrogenation and deuteration method | 瑞博(苏州)制药有限公司 | 2024-02-06 | — | — | CN | disclosed |
| US-20230128402-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | THE TRUSTEES OF PRINCETON UNIVERSITY | 2023-04-27 | — | — | US | disclosed |
| US-20230128402-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | THE TRUSTEES OF PRINCETON UNIVERSITY | 2023-04-27 | — | — | US | disclosed |
| WO-2021151062-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | THE TRUSTEES OF PRINCETON UNIVERISTY (US) | 2021-07-29 | — | — | WO | disclosed |
| US-9809575-B2 | Pharmaceutical compounds | ReViral Limited (GB) | 2017-11-07 | — | — | US | disclosed |
| EP-2776416-B1 | PHARMACEUTICAL COMPOUNDS | RE VIRAL LTD (GB) | 2016-01-13 | — | — | EP | disclosed |
| CN-104144921-A | PHARMACEUTICAL COMPOUNDS | RE VIRAL LTD | 2014-11-12 | — | — | CN | disclosed |
| US-20140308282-A1 | PHARMACEUTICAL COMPOUNDS | re: Viral Ltd (GB) | 2014-10-16 | — | — | US | disclosed |
| US-20070032554-A1 | Treatment of stuttering and other communication disorders with norepinephrine reuptake inhibitors | ELILILLY AND COMPANY A CORPORATION | 2007-02-08 | — | — | US | disclosed |
| US-20070015786-A1 | Treatment of hot flashes, impulse control disorders and personality change due to a general medical condition | ELI LILY AND COMPANY (US) | 2007-01-18 | — | — | US | disclosed |
| US-20070015786-A1 | Treatment of hot flashes, impulse control disorders and personality change due to a general medical condition | ELI LILY AND COMPANY (US) | 2007-01-18 | — | — | US | disclosed |
| US-20060241188-A1 | Treatment of pervasive developemental disorders with norepinephrine reuptake inhibitors | ELILILLY AND COMPANY (US) | 2006-10-26 | — | — | US | disclosed |
| EP-1660064-A2 | TREATMENT OF LEARNING DISABILITIES AND MOTOR SKILLS DISORDER WITH NOREPINEPHRINE REUPTAKE INHIBITORS | ELI LILLY AND COMPANY (US) | 2006-05-31 | — | — | EP | disclosed |
| EP-1651643-A2 | BICYCLIC COMPOUNDS AND COMPOSITIONS AS PDF INHIBITORS | IRM, LLC (BM) | 2006-05-03 | — | — | EP | disclosed |
| US-20050197326-A1 | Bicyclic compounds and compostions as PDF inhibitors | IRM LLC | 2005-09-08 | — | — | US | disclosed |
| WO-2005053663-A2 | NOREPINEPHRINE REUPTAKE INHIBITORS USEFUL FOR TREATMENT OF COGNITIVE FAILURE | ELI LILLY AND COMPANY (US) | 2005-06-16 | — | — | WO | disclosed |
| WO-2005020975-A2 | TREATMENT OF LEARNING DISABILITIES AND MOTOR SKILLS DISORDER WITH NOREPINEPHRINE REUPTAKE INHIBITORS | ELI LILLY AND COMPANY (US) | 2005-03-10 | — | — | WO | disclosed |
| WO-2005011611-A2 | BICYCLIC COMPOUNDS AND COMPOSITIONS AS PDF INHIBITORS | IRM, LLC (BM) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241188-A1 | Treatment of pervasive developemental disorders with norepinephrine reuptake inhibitors | SLC6A2, SLC6A3, SLC6A4 | POLB 3080/4885L3MBTL1 2442/4885SMPD1 192/4885 |
| US-20050197326-A1 | Bicyclic compounds and compostions as PDF inhibitors | PDF, FDPS, DCTPP1 | POLB 1064/4885L3MBTL1 2968/4885SMPD1 52/4885 |
| US-20070032554-A1 | Treatment of stuttering and other communication disorders with norepinephrine reuptake inhibitors | SLC6A2, SLC6A4, SLC6A3 | POLB 3035/4885L3MBTL1 3451/4885SMPD1 1047/4885 |
| US-20140308282-A1 | PHARMACEUTICAL COMPOUNDS | CYP2S1, H1-2, CBR1 | POLB 3525/4885L3MBTL1 3695/4885SMPD1 1212/4885 |
| US-20070015786-A1 | Treatment of hot flashes, impulse control disorders and personality change due to a general medical condition | SLC6A2, SLC6A4, HTR5A | POLB 4682/4885L3MBTL1 3499/4885SMPD1 623/4885 |
| US-20230128402-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PAH, ALDH2, IDH2 | POLB 752/4885L3MBTL1 4720/4885SMPD1 1844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.